Amitiza is owned by Sucampo Pharma Llc.
Amitiza contains Lubiprostone.
Amitiza has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Amitiza are:
Amitiza was authorised for market use on 31 January, 2006.
Amitiza is available in capsule;oral dosage forms.
Amitiza can be used as method for treating constipation in a patient with opioid-induced constipation by opening cic channels; method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic); method for treating constipation by opening cic channels in a mammalian subject, use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient, method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject, method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient, method for treating opioid-induced constipation, method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
The generics of Amitiza are possible to be released after 25 October, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(5 months ago) | |
US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(2 months ago) | |
US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(2 months ago) | |
US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(a month ago) | |
US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 7 months from now) | |
US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(2 years from now) | |
US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(4 years from now) |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: Method for treating constipation in a patient with opioid-induced constipation by opening cic channels; Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic); Method for treating constipation by opening cic channels in a mammalian subject; Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation; Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; Method for the long term treatment of chronic constipation in a human subject
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic